Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
13:26:03 EDT Mon 17 Aug 2026
Enter Symbol
or Name
USA
CA



Q:BLRX - BIOLINE RX LTD SPON ADR EACH REP 600 ORD SHS (P/S) - https://www.biolinerx.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
BLRX - Q0.12.68·2.780.82.71-0.05-1.86.916442.76  2.86  2.714.56  2.1612:58:26Jul 2015 min RT 2¢

Recent Trades - Last 10 of 44
Time ETExPriceChangeVolume
12:58:26Q2.73-0.0325
12:58:24Q2.73-0.0325
12:55:08Q2.71-0.05271
12:55:08Q2.70-0.063
12:55:08Q2.71-0.051
12:38:18Q2.770.0120
12:37:49Q2.770.0120
12:37:33Q2.76 20
12:37:02Q2.71-0.0560
12:36:10Q2.72-0.046

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-07-20 07:00U:BLRXNews ReleaseBioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026
2026-07-08 07:00U:BLRXNews ReleaseBioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model
2026-05-27 07:00U:BLRXNews ReleaseBioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-22 07:00U:BLRXNews ReleaseBioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
2026-05-20 07:00U:BLRXNews ReleaseBioLineRx to Report First Quarter 2026 Results on May 27, 2026
2026-05-19 07:00U:BLRXNews ReleaseBioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Derived Xenografts
2026-04-28 07:00U:BLRXNews ReleaseBioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
2026-03-26 07:00U:BLRXNews ReleaseBioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
2026-03-23 07:00U:BLRXNews ReleaseBioLineRx Reports 2025 Financial Results and Provides Corporate Update
2026-03-16 07:00U:BLRXNews ReleaseBioLineRx to Report 2025 Annual Results on March 23, 2026
2025-11-24 07:00U:BLRXNews ReleaseBioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update
2025-11-18 07:00U:BLRXNews ReleaseBioLineRx to Report Third Quarter 2025 Results on November 24, 2025
2025-11-17 07:00U:BLRXNews ReleaseBioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types
2025-09-29 07:00U:BLRXNews ReleaseBioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers